Amy Dunn
Pediatric Hematology-Oncology · Columbus, OHNPI 1194756049
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 47.0% of the total. Reporting peaked in 2023 at $54,801 and has fallen 85.5% since, to $7,943 in 2025. Among pediatric hematology-oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $901.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$61K
- HEMA Biologics, LLC$41K
- CSL Behring$13K
- F. Hoffmann-la Roche AG$4K
- Sanofi$3K
- Kedrion Biopharma Inc.$3K
- plus $4K from 6 others
Across 834 payments — averaging $1315.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$545K
- Bioverativ Therapeutics Inc.$279K
- Sanofi US Services Inc.$121K
- Novo Nordisk AS$63K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- Regeneron$28K
- plus $14K from 4 others
What the payments were for
- Consulting fees$65,34551%
- Speaking & faculty fees$26,98321%
- Travel & lodging$33,91226%
- Food & beverage$2,5782%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 55 | $60,561 |
| HEMA Biologics, LLC | 53 | $41,245 |
| CSL Behring | 14 | $12,557 |
| F. Hoffmann-la Roche AG | 1 | $4,445 |
| Sanofi | 6 | $3,250 |
| Kedrion Biopharma Inc. | 1 | $2,638 |
| Novo Nordisk | 2 | $2,185 |
| Pfizer | 5 | $1,436 |
| Genentech, Inc. | 1 | $495 |
| Genentech USA, Inc. | 1 | $109 |
| Baxter Healthcare | 3 | $44 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SevenFact$39,718
- Idelvion$9,838
- Afstyla$7,278
- HEMLIBRA$4,554
- KOATE$2,638
- Roctavian$2,386
- HEMGENIX$2,247
- NovoSeven RT$2,160
- BENEFIX$1,400
- Non-Covered Product$495
How this compares
$128,982 in reported general payments places this provider in the 95th percentile of 143 pediatric hematology-oncology providers in Ohio.
Other pediatric hematology-oncology in Columbus
- Bryce KerlinColumbus$123K
- Anthony VillellaColumbus$66K
- Sarah ObrienColumbus$30K
- Timothy CripeColumbus$26K
- Dean LeeColumbus$20K
- Ryuma TanakaColumbus$16K
- Nilay ShahColumbus$16K
- Melissa RoseColumbus$15K
- Rolla Abu ArjaColumbus$14K
- Hemalatha RangarajanColumbus$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.